Structural factors affecting affinAD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Sm

AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.

Pieczykolan JS1, Kubiński K, Masłyk M, Pawlak SD, Pieczykolan A, Rózga PK, Szymanik M, Gałązka M, Teska-Kamińska M, Żerek B, Bukato K, Poleszak K, Jaworski A, Strożek W, Świder R, Zieliński R.

Invest New Drugs. 2014 Dec;32(6):1155-66